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Study question: What are clinicians’ views about the diagnosis of polycystic ovary syndrome 
(PCOS), and how do they handle any complexities and uncertainties in practice?  
Summary answer: Clinicians have to navigate many areas of complexity and uncertainty 
regarding the diagnosis of PCOS, related to the diagnostic criteria, limitations in current 
evidence and misconceptions surrounding diagnosis, and expressed concern about the risk 
and consequences of both under- and overdiagnosis. 
What is known already: PCOS is a complex, heterogeneous condition with many areas of 
uncertainty, raising concerns about both underdiagnosis and overdiagnosis. Quantitative 
studies with clinicians have found considerable variation in diagnostic criteria used and care 
provided, as well as lack of awareness around the breadth of PCOS features and poor 
uptake of recommended screening for metabolic complications. Clinicians’ views about the 
uncertainties and complexities of diagnosing PCOS have not been explored. 
Study design, size, duration: Semi-structured telephone interviews were conducted with 
clinicians from September 2017 to July 2018 to explore their perceptions about the 
diagnosis of PCOS, including how they handle any complexities and uncertainties in practice.  
Participants, materials, setting, methods: 36 clinicians (15 general practitioners, 10 
gynaecologists and 11 endocrinologists) currently practicing in Australia, recruited through 
advertising via professional organisations, contacting a random sample of endocrine and 
gynaecology teams across Australia and snowballing. Transcribed audio-recordings were 
analysed thematically using Framework analysis.  
Main results and the role of chance: Clinicians expressed a range of uncertainties and 
complexities regarding the diagnosis of PCOS, which were organised into three areas: 1) 
establishing diagnosis (e.g. lack of standardisation regarding diagnostic cut-offs, risk of 
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misdiagnosis), 2) factors influencing the diagnostic process (e.g. awareness of limitations in 
evidence and consideration of the benefits and harms), and 3) strategies for handling 
challenges and uncertainties (e.g. using caution and communication of uncertainties). 
Clinicians also varied in their concerns regarding under- and overdiagnosis. Overall, most 
felt the diagnosis was beneficial for women provided that it was the correct diagnosis and 
time was taken to assess patient expectations and dispel misconceptions, particularly 
concerning fertility.  
Limitations, reasons for caution: There is possible selection bias, as clinicians who are more 
knowledgeable about PCOS may have been more likely to participate. Clinicians’ views may 
also differ in other countries.  
Wider implications of the findings: These findings underscore the vital need to first 
consider PCOS a diagnosis of exclusion and use caution before giving a diagnosis in order to 
reduce misdiagnosis, as suggested by clinicians in our study. Until there is greater 
standardisation of diagnostic criteria, more transparent conversations with women may 
help them understand the uncertainties surrounding the criteria and limitations in the 
evidence. Additionally, clinicians emphasised the importance of education and reassurance 
to minimise the potential harmful impact of the diagnosis and improve patient-centred 
outcomes.  
Study Funding/ competing interest(s): The study was funded by the University of Sydney 
Lifespan Research Network and an NHMRC Program Grant (APP1113532). BWM reports 
consultancy for ObsEva, Merck, Merck KGaA and Guerbet. No further competing interests 
exist.   
Trial registration number: N/A  
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Keywords: Polycystic ovary syndrome/ diagnostic criteria/ benefits and harms/ 
psychosocial/ fertility  
Introduction 
Polycystic ovary syndrome (PCOS) is a complex endocrine disorder affecting reproductive-
aged women, with prevalence estimates ranging from 4%-22.5% depending on the 
population studied and diagnostic criteria used (Skiba et al., 2018). PCOS is associated with a 
number of adverse reproductive, metabolic and psychological outcomes (Dumesic et al., 
2015). The aetiology is still unclear and appears to include a combination of environmental 
factors, genetic causes and in utero exposure (Diamanti-Kandarakis & Dunaif, 2012; Tata et 
al., 2018). There is currently no cure for PCOS, with treatment targeted at reducing 
symptoms and emphasis on a healthy lifestyle to reduce the risk of associated comorbidities 
(Teede et al., 2018). Although the Rotterdam criteria are recommended in Australian and 
international guidelines (National Institute of Health, 2012; Teede et al., 2018; Teede et al., 
2011), two other sets of diagnostic criteria are in use (Table I). 
 
Along with multiple diagnostic criteria, there are clinical uncertainties and complexities 
regarding diagnosis. Symptoms are on a broad spectrum of severity, and it can be difficult to 
differentiate normal variability from the abnormality of PCOS (Skiba et al., 2018). PCOS is 
also a diagnosis of exclusion, as many conditions mimic symptoms of PCOS (Azziz et al., 
2006). Women can see a range of different healthcare providers (e.g. general practitioners, 
endocrinologists, gynaecologists) depending on their primary symptoms, which also vary by 
age, weight and ethnicity (Dokras & Witchel, 2014). Additionally, diagnostic criteria have 
been mostly based on expert consensus rather than clinical evidence, and have led to 
substantial debate (Azziz, 2006; Skiba et al., 2018; Wang & Mol, 2017). These complexities 
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have contributed to inconsistent approaches to diagnosis (Conway et al., 2014; Dokras et 
al., 2017), with many women reporting significant dissatisfaction with the diagnostic 
experience and information provided, including delays in receiving a diagnosis (Gibson-Helm 
et al., 2017). This has raised concerns about underdiagnosis, as a timely diagnosis is thought 
to enable early treatment of symptoms, fertility counselling and early engagement in 
lifestyle management to prevent weight gain and related metabolic complications (Gibson-
Helm et al., 2017).  
 
Adding to the complexity, diagnostic criteria for PCOS expanded to include polycystic 
ovaries, increasing the number of women diagnosed and raising concerns about 
overdiagnosis (Copp et al., 2017). In addition, some phenotypes introduced by the 
expanded Rotterdam criteria (i.e. those with normal androgen levels) do not seem to have 
the same increased health risks as the original National Institute of Health phenotype (Daan 
et al., 2014; Lizneva et al., 2016). Furthermore, current evidence is limited by referral bias, 
with most studies recruiting from specialist clinics and PCOS support groups, where women 
with more severe symptoms are more likely to be (Azziz et al., 2016; Lizneva et al., 2016). It 
is uncertain how the existing evidence applies to the different phenotypes and women with 
milder symptoms.  
 
Little is known about how clinicians handle the uncertainty surrounding PCOS diagnosis. A 
limited number of studies have found marked differences between general practitioners, 
endocrinologists and gynaecologists regarding diagnostic tests used and medication 
prescribed for PCOS (Cussons et al., 2005; Powers et al., 2015). Online surveys in various 
countries have also found considerable variation in care, lack of awareness around the 
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breadth of PCOS features, as well as poor uptake of regular screening for metabolic 
complications as recommended in guidelines (Dhesi et al., 2016; Gibson-Helm et al., 2018). 
Additionally, many clinicians reported not using the Rotterdam criteria or were unaware of 
which criteria they used (Asante et al., 2015; Dokras et al., 2017), despite these criteria 
being recommended in several guidelines since 2011 (National Institute of Health, 2012; 
Teede et al., 2018; Teede et al., 2011). In light of these findings, this study aimed to 
understand clinicians’ views about the diagnosis of PCOS, and explore how they manage any 
complexities and uncertainties in clinical practice.   
 
Materials and Methods 
Design 
This qualitative study used semi-structured interviews to explore clinicians’ experiences and 
views about the challenges and complexities of diagnosing PCOS (Supplementary Table SI).  
 
Ethics approval 
Study methods were approved by The University of Sydney Human Research Ethics 
Committee (2017/243). All participants provided written informed consent.  
 
Participants and recruitment  
Participants were clinicians from the key disciplines directly involved in the diagnosis of 
PCOS. A multifaceted strategy was utilised to ensure a diverse sample of Australian 
clinicians were recruited. This included advertising via newsletters or social media accounts 
of relevant professional organisations, contacting a random sample of endocrine and 
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gynaecology teams across Australia using publicly available contact details, and through 
active and passive snowballing with the help of collaborators and participants.  
 
Data collection 
The semi-structured interview guide was developed by the whole research team, piloted 
with a clinician from each specialty and reviewed by the team’s PCOS consumer panel 
(consisting of three women who identify across the spectrum of PCOS symptom severity). 
Topics included thoughts about the diagnosis and diagnostic criteria, any challenges and 
uncertainties, communication with patients, and perceived benefits and harms of the 
diagnosis (Supplementary Data B). Interviews were conducted by phone between 
September 2017 and July 2018, lasted 20-60 minutes and were audio-recorded and 
transcribed verbatim.  
 
Analysis 
Data were analysed thematically using Framework analysis to understand clinicians’ 
experiences and perspectives (Ritchie, 2003). Framework analysis uses a matrix-based 
approach with columns depicting themes and rows listing the cases, enabling the 
relationships between themes and cases to be explored (Ritchie & Spencer, 1994). The first 
step involved familiarisation with the data, where one researcher reviewed the transcripts 
and developed a list of emerging topics and salient themes. These initial impressions, along 
with the interview guide and field notes, formed the basis of the coding framework. An 
additional four researchers independently read a subset of transcripts and reviewed the 
framework, which was then further revised with continuous discussion. One researcher 
coded all the interviews into the final framework, with a random subset (10%) double-coded 
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by an additional researcher to ensure rigour. Similarities or differences were discussed and 
re-assessed. Prominent themes arising from the framework were identified and discussed 
in-depth with the research team. 
 
Results 
Participant characteristics   
The 36 participants varied in years of experience and included 15 general practitioners 
(GPs), 10 gynaecologists (3 of whom were also reproductive endocrinologists) and 11 
endocrinologists (including 1 paediatric endocrinologist), working in a mix of both public and 
private practice (Table II). Most participants mentioned using the Rotterdam diagnostic 
criteria. The most common symptoms women presented with differed according to clinical 
specialty (e.g. GPs-irregular menstrual cycles, endocrinologists-weight gain and androgen 
excess, and gynaecologists-irregular menstrual cycles and infertility).  
 
Thematic analysis 
Findings were organised into three overarching areas: 1) establishing diagnosis, 2) factors 




Uncertainties surrounding the diagnosis of PCOS  
The majority of clinicians reported using the Rotterdam criteria in adult women, and 
discussed how they are “useful” in capturing the broad syndrome, facilitating research and 
are easy to apply.  
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“It’s handy for us as GPs because you’ve got something to follow.” (ID5, GP, 
practicing 5 years)  
At the same time, many also discussed how the Rotterdam criteria are not “perfect” and 
that for many women the diagnosis is borderline or unclear.  
“Sometimes it’s very hard to say when the normal finishes and the abnormal begins.” 
(ID26, Endo, practicing 25 years)  
Many discussed how polycystic ovaries are very common and almost “a normal variant”, 
and that “people can flop in and out of being diagnosed” as biochemical profiles and 
ultrasound findings can change over time, causing “a lot of confusion and distress for 
patients” (ID20, Gyn, practicing 16 years). Some clinicians, particularly GPs, described how 
interpreting blood results can be “challenging” due to lack of standardised cut-offs. A few 
also commented that the guidelines don’t acknowledge the role of insulin resistance, which 
they viewed as central to PCOS. Most GPs reported always ordering ultrasounds, even if 
other criteria had been met for diagnosis.  
“I think sometimes I may be guilty of I’ve already got enough information to make 
the diagnosis and I still order the ultrasound anyway.” (ID11, GP, practicing 3 years)  
However, many specialists and a few GPs commented on how ultrasounds are unhelpful, 
variable in quality and a “waste of time” (ID23, Gyn, practicing 29 years) as they don’t alter 
management.  
 
Problems with misdiagnosis  
Many clinicians stressed the importance of considering PCOS a diagnosis of exclusion, using 
clinical insight and taking a thorough history, as “misdiagnosis is a big issue” (ID18, Gyn, 
practicing 17 years). They described how it can be “difficult to untangle what really is the 
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problem” (ID20, Gyn, practicing 16 years) because many other factors can mimic PCOS 
symptoms, such as stress, contraceptive use, Cushing’s syndrome, obesity, hypothalamic 
amenorrhea or disordered eating.  
“Often I do get women coming saying oh yes, I’ve got polycystic ovarian syndrome, 
I’ve been diagnosed by a GP. And the only syndrome they have is obesity.” (ID34, 
Endo, practicing 15 years) 
Some discussed how emphasis on ultrasounds can result in misdiagnosis, as “people tend to 
believe the ultrasound and often don’t do blood tests, and often they turn out to have 
something else.” (ID23, Gyn, practicing 29 years). For some specialists, misdiagnosis is their 
biggest concern as it stops patients from receiving appropriate and timely treatment for 
their actual condition.  
“You don’t treat the condition that they actually have. I’ve just recently diagnosed 
someone with an unresolved eating disorder who came to me with PCOS. But she 
doesn’t [have PCOS]. She’s actually anorexic. So you have to be quite careful in how 
you treat people.” (ID21, Gyn, practicing 22 years)  
The majority of clinicians also discussed how diagnosing PCOS in adolescents is “fraught 
with danger” as symptoms overlap with normal signs of pubertal development, so it is 
“reasonable to tread carefully with adolescents and delay making a diagnosis” (ID25, Gyn, 
practicing 3 years). 
 
Factors influencing the diagnostic process 
Prioritising avoidance of underdiagnosis or overdiagnosis  
Clinicians varied widely regarding the factors that influence their decision making. Some GPs 
perceived underdiagnosis as the main risk and timely diagnosis the biggest challenge.  
Clinicians’ views of polycystic ovary syndrome 
 
11 
"We don’t necessarily sort of screen for it [PCOS] and some people think that 
irregular periods are normal. So I think we have to be quite proactive.” (ID7, GP, 
practicing 5 years) 
For many clinicians, particularly GPs, a diagnosis is important because it starts discussions 
about optimal health and facilitates a holistic, collective approach to symptom 
management. A few clinicians discussed how they would rather overdiagnose than 
underdiagnose PCOS, as healthy lifestyle recommendations are beneficial for everyone and 
any medical treatment is justified by bothersome symptoms.  
“I think it’s actually better if anything to slightly overdiagnose than underdiagnose. 
Because if you can get women into these healthy lifestyle changes and stuff, this is 
good for everybody.” (ID7, GP, practicing 5 years)  
 
On the other hand, some clinicians expressed that overdiagnosis was their “biggest 
concern” and that the condition was being “overplayed” (ID30, Endo, practicing 30 years). 
Some using the Rotterdam criteria reported feeling they easily capture a lot of women, and 
“if you look hard enough” you can diagnose women who are not concerned about 
symptoms or seeking a diagnosis, causing unnecessary worry (ID5, GP, practicing 5 years). 
Others reported using alternative diagnostic criteria or clinical expertise, as they believe 
“excess of androgens should be a mandatory element” (ID15, GP, practicing 10 years) to 
avoid both misdiagnosis and overdiagnosis.  
“I use the AES criteria for diagnosis. I think the Rotterdam criteria are completely 
outdated and lead to an almost, over- and misdiagnosis with significant 
consequences. There are lots of women who are overdiagnosed or misdiagnosed with 
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PCOS on the basis of irregular cycles and polycystic appearance of the ovaries on 
ultrasound.” (ID24, Gyn, practicing 21 years) 
Many endocrinologists discussed how PCOS is “a condition that has evolved with our social 
environment” (ID30, Endo, practicing 30 years) due to increasing rates of obesity, expressing 
concerns that the diagnosis is medicalising a societal phenomenon. Some discussed the 
challenge of determining whether it is obesity causing symptoms suggestive of PCOS or 
whether obesity is a manifestation of the condition.  
“I think the label of PCOS is just bandied about so often, I probably actually spend 
more time telling women I don’t think they have true PCOS.” (ID31, Endo, practicing 
18 years)  
These clinicians perceived that “over-medicalising” and labelling weight issues as PCOS 
undermines patients’ sense of “agency” and control over their weight, while recognising 
patients’ preference for a medical explanation of their obesity (ID35, Endo, practicing 28 
years).  
 “I’m not sure that we do people any favours by giving them a label. You might be 
also setting them up for failure by giving them a label to something that they may 
not necessarily have and then the treatments probably won’t necessarily help their 
situation.” (D34, Endo, practicing 15 years)  
Distinct from these attitudes, gynaecologists who worked in private fertility clinics often 
viewed that giving the diagnosis was not relevant as it made no difference to fertility 
treatment.  
"It doesn’t really matter to me [whether PCOS is diagnosed or not]. It’s more a case 
of whether they’re ovulating or not." (ID22, Gyn, practicing 18 years) 
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Perceived benefits and harms for women diagnosed 
When considering the impact of the diagnosis, a number of perceived benefits and harms 
were discussed (see Table III for illustrative quotes). Many clinicians considered a range of 
benefits, such as providing an explanation for symptoms and enabling early intervention to 
maintain optimal metabolic health and fertility. A few also discussed how the diagnosis 
enables lifestyle to be addressed in a non-stigmatising way. Regarding harms, some 
clinicians discussed how the diagnosis can have a negative psychological impact, as “there’s 
a lot of anxiety about PCOS, especially among young women” (ID25, Gyn, practicing 3 years). 
Several clinicians discussed the negative impact of labelling young women with a chronic 
disease, as “labels stick like glue” (ID30, Endo, practicing 30 years), cause ongoing concerns 
about their health and impact how they view themselves. This was particularly significant 
for adolescents, as the label makes no difference to management and adolescents have “all 
the anxiety around the diagnosis but potentially not the resources or the maturity to 
manage it” (ID26, Endo, practicing 25 years).  
Clinicians varied in weighing the benefits and harms. A few thought the diagnosis could 
cause more harm than benefit, particularly for those with mild symptoms. Some felt that 
although the diagnosis carried some stigma, it was still important to know as it gave women 
“a clear way forward”. Others described feeling “in two minds”, as it can help women plan 
ahead but the long-term benefits are unclear and it may cause more grief than required. 
Overall, most viewed the label as helpful “as long as she has it in perspective that she 
doesn’t necessarily have to get all of the disaster consequences of the label” (ID20, Gyn, 
practicing 16 years). 
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Strategies for handling challenges and uncertainties 
Caution with labelling when there is uncertainty 
Many clinicians across specialties discussed challenges with managing women for whom the 
diagnosis is unclear. Approaches for communicating with these patients varied and were 
influenced by the patient’s age and expectations (e.g. whether they had already self-
diagnosed PCOS). Some clinicians discussed how they communicate the possibility of PCOS, 
and explain that time is needed to confirm the diagnosis.  
“I say it may be PCOS, but I’m uncertain and I don’t want to make that diagnosis now.” 
(ID21, Gyn, practicing 22 years) 
Other clinicians, particularly those concerned about the negative impact of disease labelling, 
described avoiding the label entirely and focusing on treating bothersome symptoms and 
encouraging a healthy lifestyle. This strategy, however, is not always successful if patients 
(or their parents in the case of adolescents) insist on a diagnosis.  
“We just have to be very cautious in labelling them with conditions that are going to 
stay with them for a long time if there’s any level of uncertainty.” (ID30, Endo, 
practicing 30 years) 
A few endocrinologists described the challenge in managing patient expectations of 
receiving a diagnosis, given that “most people have Googled their symptoms” (ID31, Endo, 
practicing 18 years). They suggested that the use of incorrect or premature diagnostic labels 
may be driven by a desire for certainty on the part of both clinicians and patients.  
“I think some medical people don’t like to be uncertain. And patients sometimes want 
to have some sort of certainty too. But I don’t think we should just necessarily 
pretend that it’s certain when it’s not.” (ID34, Endo, practicing 15 years) 
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Tailoring care and communication 
Although some clinicians reported communicating all of the associated long-term risks to all 
diagnosed patients, many emphasised the need for patient-centred communication and 
how the clinical context and patient goals should determine the information provided.  
“The challenge that faces us as clinicians is we’re not just labelling people within a 
criteria, we also have to address the human element and communicate in a way 
that’s appropriate to that patient, to give that patient the best outcome.” (ID25, Gyn, 
practicing 3 years)  
Many clinicians discussed explaining to patients that PCOS varies on a spectrum of 
presentations and severity, and how they felt that this minimises the fear of associated 
adverse consequences.  
"I talk about it to women as a concept and a group of issues, rather than a discrete 
disease or diagnosis...I think the diagnosis is too difficult and flawed to apply rigidly. 
So I kind of see it as a spectrum." (ID32, Endo, practicing 15 years)  
 
Education and reassurance vital in minimising harm  
Misinformation surrounding PCOS was a key issue raised by the majority of clinicians. 
Infertility was the most common misconception, with most clinicians reporting that women 
read online or are told by a doctor that they will not be able to conceive naturally.  
“They’re often being told they can’t get pregnant. That’s one of the most disturbing 
things I hear many times a day.” (ID23, Gyn, practicing 29 years)  
Many clinicians, particularly specialists, discussed how providing accurate information and 
reassurance was crucial to dispel myths, manage expectations and minimise the potential 
for harm. In particular around reduced fertility, some discussed the importance of  
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communicating that “lots of women with PCOS manage to fall pregnant naturally without 
any intervention” and that “if they don’t want to fall pregnant then they need to use some 
form of contraception. They can’t just rely on being sub-fertile” (ID7, GP, practicing 5 years). 
Clinicians expressed that sensitively communicating the possibility of fertility problems and 
dispelling these myths was challenging and time consuming as “it doesn’t take very much for 
women to doubt their fertility” (ID2, GP, practicing 7 years) and women needed a lot of 
reassurance. 
“I have an hour’s discussion with the patient, getting rid of all the information she’s 
been given by other people. But undoing that is a tremendous amount of work.” 
(ID23, Gyn, practicing 29 years)  
Other clinicians’ narratives, however, suggested that they overtly discussed the associated 
risks at the time of diagnosis, noting that “knowledge is always power”. This included 
statements about cardiovascular disease, despite uncertainties around likelihood.  
“Even in the skinny ones I’ll talk about cardiovascular risk, ‘cause I know that they’ve 
still got the cardiovascular risks associated with the insulin resistance, even if they’re 
not actually overweight” (ID6, GP, practicing 3 years)  
Overall, most discussed how it is vital to deliver the diagnosis in a positive and encouraging 
way so the patient is “empowered to try and take control of her long-term metabolic 
health”, rather than walk away with a defeatist, despairing outlook “thinking that they’re 
going to end up needing to shave and wear a wig because of alopecia, be infertile and then 








Clinicians described experiencing a range of uncertainties and challenges regarding PCOS 
diagnosis. These related to diagnostic criteria (e.g. lack of standardised cut-offs, risk of 
misdiagnosis, unclear utility of ultrasounds) and their perception of the diagnosis overall 
(e.g. limitations in evidence, possible benefits and harms for patients). Clinicians also varied 
in their concerns regarding PCOS, influenced by their awareness of the uncertainty 
surrounding diagnosis and considerations of benefits and harms. They either favoured early 
diagnosis to maximise timely engagement and prevent weight gain and related metabolic 
complications, had a more critical stance towards limitations in evidence and raised 
concerns about premature or unnecessary labelling, or were in two minds, still weighing up 
the benefits and harms. Overall, most felt the diagnosis was beneficial for women provided 
it was the correct diagnosis and time was taken to assess patient expectations and dispel 
misconceptions (e.g., women thinking they will never be able to conceive naturally).  
 
This work builds on findings from quantitative research (Dokras et al., 2017) showing that 
whilst the majority of clinicians use the Rotterdam criteria to diagnose PCOS, many use and 
interpret these criteria in different ways. This variation is due to the uncertainties and 
complexities that exist when trying to apply the criteria to a heterogeneous condition with 
substantial phenotypical variation and overlap with other conditions. These uncertainties 
are exacerbated by the substantial debate surrounding the diagnostic criteria (Azziz, 2006; 
Lizneva et al., 2016; Wang & Mol, 2017), the unclear benefits and harms of the diagnosis in 
the long-term (Copp et al., 2017), and the still limited understanding of the aetiology of 
PCOS (Azziz et al., 2016). In light of this, many clinicians in this study cautioned to take time 
when establishing the diagnosis to avoid labelling prematurely or inaccurately, particularly 
Clinicians’ views of polycystic ovary syndrome 
 
18 
for adolescents. Indeed, new international guidelines now recommend that adolescents 
with an unclear diagnosis should be regarded ‘at risk’ and reassessed later to reduce the risk 
of overdiagnosis (Teede et al., 2018). These diagnostic complexities could also explain why 
some women report long delays and seeing multiple doctors before receiving a diagnosis 
(Gibson-Helm et al., 2017). Expanding quantitative findings (Dokras et al., 2017), clinicians 
who had been practicing longer seemed more cautious with diagnosing and less likely to use 
the Rotterdam criteria, expressing a view that these criteria increase misdiagnosis and 
overdiagnosis. Although there was variation within specialties, key diagnostic concerns also 
seemed to differ across specialties, with more GPs concerned about underdiagnosis, 
gynaecologists about misperceptions and endocrinologists about overdiagnosis.   
 
As well as recognising the complexities associated with diagnosing PCOS, participants 
acknowledged both benefits and harms of a PCOS diagnosis for patients, although 
considerations of harms varied widely. Participants’ perceived benefits and harms are 
consistent with previous research on disease labelling, which suggests that labels can 
provide validation and increase patients’ understanding and ability to cope (Copp et al., 
2019), but can also induce feelings of anxiety and hopelessness (Haynes, 1978; Scherer et 
al., 2013; Shaffer & Scherer, 2018). There were particularly varying views regarding lifestyle 
changes. Whilst some clinicians thought the diagnosis could cause harm by undermining 
women’s sense of control over their weight and result in disengagement with healthy 
lifestyle changes, many believed the diagnosis enabled early engagement in lifestyle 
management to prevent weight gain and related metabolic complications. This presumed 
benefit contrasts with mounting evidence showing that personalised risk information does 
not change behaviour (French et al., 2017; Hollands et al., 2016; Marteau, 2018), suggesting 
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clinicians may be overestimating this potential benefit. Views also differed in how helpful 
the diagnosis was in guiding management.  
 
Importantly, these findings underscore the crucial need to consider PCOS a diagnosis of 
exclusion and complete the recommended work-up to reduce misdiagnosis. The new 
international guidelines attempt to address some of these uncertainties raised by clinicians 
by clarifying the diagnostic criteria. For example, the definition of oligomenorrhea has been 
more clearly defined and the antral follicle count for polycystic ovary morphology has been 
increased to >20 to account for increasing sensitivity of imaging technology (Teede et al., 
2018). A diagnosis of PCOS should not be assigned lightly, as it implies an increased risk of a 
myriad of adverse reproductive, metabolic and psychological consequences, may mandate 
chronic treatments and regular screening for comorbidities, and could potentially affect 
health insurance premiums (Azziz et al., 2006). An incorrect PCOS diagnosis also means 
women miss out on correct treatment. For example, untreated hypothalamic amenorrhea, 
which was reported to be frequently misdiagnosed as PCOS, can have significant 
implications such as bone loss (Shufelt et al., 2017).  
 
Notably, many specialists spent additional time educating the patient regarding her fertility 
potential and undoing misinformation, sometimes perpetuated by other clinicians. 
Appropriate education of clinicians and counselling of patients regarding the chances of 
spontaneous ovulation, need for contraception and fertility over the reproductive span is 
urgently needed. Additionally, physicians need appropriate education regarding the 
associated comorbidities as these risks differ amongst women with different symptoms, 
enabling tailored risk counselling. For uncertain cases, more transparent conversations with 
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women may help them understand the uncertainties surrounding the criteria, explaining 
why clinicians may be hesitant to give a diagnosis. This may reduce dissatisfaction 
associated with delayed diagnosis whilst still providing rapid and appropriate treatment of 
bothersome symptoms. Communicating uncertainty however is challenging, and more 
research in this area is needed.  
 
Strengths of this study include the varied recruitment method to ensure a diverse sample of 
physicians from the key disciplines involved in PCOS healthcare in Australia; general 
practitioners, gynaecologists and endocrinologists. Additionally, the interview guide was 
developed by a multidisciplinary team to ensure relevance, including researchers 
experienced in qualitative methodology, PCOS experts and PCOS consumers, and rigorous 
qualitative analysis was undertaken to reach final themes. A possible limitation is potential 
selection bias, as physicians more knowledgeable or experienced with PCOS may have been 
more likely to participate. However, given the variation in perspectives reported and range 
in years of experience, strong selection bias is unlikely. These views may also differ from 
those of clinicians in other countries. Further research on clinicians’ views in different 
locations and different healthcare systems is warranted. 
 
In conclusion, these findings provide valuable insight into clinicians’ experiences with the 
PCOS diagnostic criteria and the complexities regarding diagnosis in Australia, highlighting 
concerns about the risk and consequences of both underdiagnosis and overdiagnosis. 
Additionally, misdiagnosis was raised as a key issue, underscoring the crucial need to first 
exclude mimicking conditions. These findings also suggest some clinicians are concerned 
about giving a diagnosis when there is uncertainty because disease labels and their attached 
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implications are hard to remove once given. Effective communication and tailored care may 
be a way to minimise the potential harmful impact of the diagnosis, dispel misconceptions 
and improve patient-centred outcomes.  
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